Newsroom
The Latest News From the Ivy Center
The Ivy Brain Tumor Center at Barrow Neurological Institute strives to be a valuable resource for any brain tumor or brain cancer-related media needs. Our media relations team is happy to help answer questions and arrange interviews. The expert neurosurgeons, neuro-oncologists and scientists at the Ivy Center are available to speak on a variety of topics.
Our state-of-the-art media studio is available for audio and video interviews. We can also arrange filming opportunities at various locations around the center and labs.
To contact the media relation team, call Jennifer Keeler at 602-670-4400 or email: [email protected].
Please see below for the latest media coverage and news from the Ivy Center. To read about our inspiring patients and those behind the scenes at the Ivy Center, visit the Ivy Blog.
Our Bioscience Economy
The Ivy Brain Tumor Center was recognized in a cover story by Greater Phoenix InBusiness as a top-ranked healthcare organization that provides top-notch care, innovation, and research excellence. Learn more -->
Our Bioscience Economy
InBusiness Phoenix Magazine's latest cover story they detail the Ivy Brain Tumor Center as one of the "top-ranked healthcare organizations that provide top-notch care, are innovative and known for research excellence.”
Ivy Brain Tumor Center Evaluates AZD1390 in Patients Diagnosed with Recurrent Grade IV Gliomas
A research team at the Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer, will evaluate AZD1390 in a Phase 0/1b clinical trial with patients diagnosed with recurrent grade IV gliomas. Onco'Zine covers the full trial and provides more details in this article.
Ivy Brain Tumor Center Opens New Clinical Trial for Patients with Recurrent Grade IV Gliomas
Ivy Brain Tumor Center is conducting a new clinical trial for patients with recurrent Grade IV gliomas. Learn about the study and how it could improve brain cancer treatments.
Arizona on the Cutting Edge of Innovative Research Programs
Read about Ivy Brain Tumor Center's innovative research programs and how they are advancing brain cancer treatments. Learn how they are leading the way in Arizona and beyond.
Dr. Stuart Marcus Creates SonALAsense To Treat Deadly Cancers
The Ivy Brain Tumor Center collaborates with SonALAsense to conduct clinical trials that will rapidly assess a minimally invasive drug-device combination therapy in patients with glioblastoma. Dr. Stuart Marcus founder of SonALAsense discusses his journey with cancer research and how it led him to the discovery of this therapy.
Valley nurse fighting brain cancer sees promising results from treatment
Tim Jackson, a valley nurse, was diagnosed with brain cancer in February 2021. Tim and his wife, Amber, joined ABC15 to discuss their journey with glioblastoma and their exploration of clinical trials at the Ivy Brain Tumor Center. Read his full story here.
The Game On Glio Podcast: Episode 10 with Guest Dr. Sanai
Dr. Nader Sanai, director of Ivy Brain Tumor Center, joined Shannon Traphagen, Host of the “Game on Glio” podcast, to share his career in neurosurgical oncology. Dr. Sanai discusses the work happening at the Ivy Brain Tumor Center and the progress being made toward discovering a cure for brain cancer.
Ivy Brain Tumor Center’s core labs earn accreditation
The Ivy Brain Tumor Center is pleased to announce that its Pharmacodynamics (PD) Core and Pharmacokinetics (PK) Core laboratories passed their inspection and maintained accreditation by the Accreditation Committee of the College of American Pathologists (CAP). Learn more ->
Ivy Brain Tumor Center’s Core Laboratories Awarded Accreditation by the College of American Pathologists
The Ivy Brain Tumor Center, the largest early-phase drug development program for brain cancer in the world, announced that its Pharmacodynamics (PD) Core and Pharmacokinetics (PK) Core laboratories passed their inspection and maintained accreditation by the Accreditation Committee of the College of American Pathologists (CAP).